Mabwell Biopharma and DeepModeling Announce Strategic Collaboration to Advance AI for Science-Powered Innovative Drug Discovery

Mabwell (688062.SH), an innovative biopharmaceutical company with a fully integrated industrial chain, and DP Technology jointly announced a strategic partnership. The two parties will leverage their respective strengths in biopharmaceutical R&D and artificial intelligence (AI) large model fields to jointly build a large model platform for biopharmaceutical R&D and establish a new paradigm for innovative drug development.

Mabwell has outstanding advantages in the construction of the ADC technology platform, discovery of single/dual antibody molecules and other fields, and has established a complete industrial chain for ADC drugs from R&D to production. Its self-developed IDDC™ platform and Mtoxin™ toxin technology have been validated in multiple projects. DP Technology, with its self-developed series of large life science models such as the Uni-Smart multimodal scientific literature large model, Uni-Mol molecular conformation large model, and Uni-Fold protein folding large model, has built a complete cognitive and computational system for the microscopic world. The two parties will cooperate in the following two directions:

1) Knowledge Engine Construction: Relying on the Uni-SMART multimodal scientific literature large model to build a biotech innovation drug research and development knowledge engine, achieving precise intelligent screening of scientific literature, identifying and extracting multimodal elements, and enabling comprehensive and in-depth analysis and interpretation. This constructs a rich and reliable target database, significantly improving research efficiency and accelerating the analysis and R&D process.

2) Innovative Target Exploration: The RiDYMO® high-quality Hit discovery and optimization platform can unlock the kinetic mechanisms of difficult-to-drug targets, exploring a broader molecular chemical space. Its core algorithm, the enhanced kinetic RiD, can increase molecular simulation sampling efficiency by nearly a hundred times, effectively capturing dynamic conformational changes in biomacromolecules. The collaboration will integrate Mabwell's ADC technology advantages with DP Technology's RiDYMO® platform strengths to jointly explore breakthrough innovative target mechanism research, accelerating drug molecule discovery from 0 to 1.

Mabwell Actively Promotes the Deep Integration of Biomedicine and AI Technology to Empower Innovative Drug Development. This collaboration will drive biopharmaceutical R&D from "experiment-driven" to "computation-driven," further enhancing R&D efficiency and bringing patients more effective and accessible biologic innovations to meet unmet clinical needs worldwide.

　　AboutDP Technology

DP Technology is a global leader in AI for Science. AI for Science refers to the use of AI to learn a series of scientific principles and knowledge, and further address key issues in scientific research and industrial R&D.

Relying on the deep cultivation in the field of interdisciplinary research, DP Technology has built the "Deep Potential•Universe" AI for Science large model system, further addressing key issues in scientific research and industrial development. This effort transitions research methodologies across numerous disciplines from the "experimental trial-and-error/computer" era into the "pre-trained model era." It establishes an "innovation-to-application" pipeline and open ecosystem for AI for Science, constructs micro-scale industrial infrastructure based on AI for Science, and empowers "diverse industries." This new generation of industrial R&D systems is designed to advance fundamental economic sectors such as biomedicine, energy, materials, and information science and engineering research.

DP Technology is a national high-tech enterprise and a national specialized and sophisticated "little giant" enterprise, with research and development centers located in cities such as Beijing, Shanghai, and Shenzhen. The scientific research team is led by an academician of the Chinese Academy of Sciences, gathering over a hundred outstanding young scientists and engineers from various fields including mathematics, physics, chemistry, biology, materials, and computer science. Among them, PhDs and postdoctoral researchers account for more than 35% of the company's members. Core members have received the "Gordon Bell Prize," the highest award in the global high-performance computing field in 2020, and their related work was selected as one of China’s top ten scientific advances in 2020 and one of the ten major technological breakthroughs in the global AI field.

　　About Mabwell

Mabwell (688062.SH) is an innovative biopharmaceutical company with a fully integrated industrial chain layout. Adhering to the vision of "turning innovation from dreams into reality" and fulfilling the mission of "exploring life, benefiting health," Mabwell provides patients with bio-innovative drugs that offer better efficacy and greater accessibility through original innovation, addressing unmet clinical needs globally. Since its establishment in 2017, Mabwell has built an innovative system covering the entire drug R&D cycle, starting from antibody drug target discovery and molecular discovery, and encompassing druggability research, preclinical research, clinical research, and production transformation, achieving an all-in-one layout of R&D, production, and marketing. We focus on cancer and age-related diseases, involving treatment areas such as oncology, autoimmune diseases, bone diseases, ophthalmology, hematology, and infectious diseases. With internationally leading proprietary technology platforms and R&D innovation capabilities, we have established a rich and competitive pipeline. Currently, there are 16 varieties at different stages, including 12 innovative varieties and 4 biosimilars, among which 3 varieties are marketed, one variety's drug marketing authorization application has been accepted, and 3 varieties are in pivotal registration clinical trial stages. Mabwell independently undertakes one national major scientific and technological project under the "Major New Drug Creation" program, two key national R&D plans, and multiple provincial and municipal science and technology innovation projects. Rooted in innovation and emphasizing industrial transformation, Mabwell’s antibody and recombinant protein drug industrialization base, compliant with China NMPA, U.S. FDA, and EU EMA GMP standards, has been put into operation in Taizhou, Jiangsu, and has passed the EU QP audit. Large-scale commercial production bases in Jinshan, Shanghai, and Taizhou, Jiangsu, are currently under construction. For more information, please visit: www.mabwell.com.